TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.15M | $67.79M | n/a | −1 |
| Q2 2026 | 113 | +16 | 68.20M | $3.64B | +20 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 2.95M | n/a | $24.24M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.20M | n/a | $18.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (pasivo) | 1.67M | n/a | $13.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | D. E. Shaw & Co. ✦ | 1.53M | n/a | $12.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 640.31K | n/a | $5.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 400.00K | n/a | $3.29M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 320.58K | n/a | $2.64M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 314.18K | n/a | $2.58M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 74.07K | n/a | $608,848 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Wellington Management ✦ | 72.66K | n/a | $597,249 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Norges Bank ✦ (pasivo) | 71.00K | n/a | $583,620 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 43.18K | n/a | $354,956 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 33.44K | n/a | $275,000 | 0.0% | n/c | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 121.20K acciones, $3,600 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 78.40K acc. · $4.31M
Officer, Director · 37.27K acc. · $2.02M
Officer, Director · 128.06K acc. · $6.78M
Officer · 8.28K acc. · $538,917
Officer, Director · 101.69K acc. · $6.57M
Officer, Director · 6.80K acc. · $441,795
Officer, Director · 99.72K acc. · $6.31M
Officer · 79.11K acc. · $5.04M
Officer · 93.60K acc. · $5.92M
Officer, Director · 96.12K acc. · $6.12M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología